Aptose Biosciences (NASDAQ:APTO) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a note issued to investors on Wednesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $2.00 price target on shares of Aptose Biosciences in a research note on Tuesday, December 10th.

Aptose Biosciences Stock Down 0.2 %

APTO opened at $0.23 on Wednesday. The business has a fifty day simple moving average of $0.26 and a 200-day simple moving average of $0.42. The firm has a market cap of $13.67 million, a PE ratio of -0.08 and a beta of 0.87. Aptose Biosciences has a fifty-two week low of $0.13 and a fifty-two week high of $2.60.

Institutional Trading of Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp boosted its holdings in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 401,750 shares of the biotechnology company’s stock after buying an additional 167,282 shares during the period. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.